Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech develops and manufactures biosimilar medicines for global markets. Company news centers on its approved and marketed biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, along with disclosed candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer.
Recurring updates cover financial results, annual reporting, FDA interactions tied to the Reykjavik manufacturing facility, biosimilar study results such as AVT80, supply and commercialization partnerships, intellectual-property settlements, executive changes and manufacturing-platform developments. Alvotech also reports on global commercial reach through partners across the United States, Europe, Japan, China and other international markets.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management team will engage in an in-person fireside chat on September 5, 2024, at 5:35 pm EDT (21:35 GMT).
Investors and interested parties can access a live audio webcast of the fireside chat through Alvotech's investor website in the events section. For those unable to attend live, a recording will be archived and available for at least 90 days after the event, providing an opportunity to gain insights into Alvotech's strategies and developments in the biosimilar market.
Alvotech (NASDAQ: ALVO) reported record financial results for Q2 and H1 2024, with total revenues reaching $236 million in H1, a ten-fold increase year-over-year. Product revenues grew 190% to $66 million, while license and other revenues surged to $170 million. The company achieved positive Adjusted EBITDA of $64 million in H1, compared to a loss of $147 million in the same period last year.
Key highlights include:
- U.S. order book for biosimilar Humira increased to 1.3 million units for 2024
- Successful launches of biosimilars in multiple markets
- Positive clinical results for AVT03, a proposed biosimilar to Prolia® and Xgeva®
- Expanded partnerships with STADA and Advanz Pharma
- Refinancing of debt obligations, improving overall debt profile
Alvotech (NASDAQ: ALVO) and Advanz Pharma announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept). The approval process is expected to be completed by Q3 2025. This development marks a significant step towards making AVT06 available in Europe, potentially benefiting patients and caregivers.
Alvotech is responsible for AVT06's development and commercial supply, while Advanz Pharma holds exclusive commercialization rights in Europe, except for France and Germany. In 2023, Eylea® sales in Europe reached $2.9 billion, with global sales totaling $5.9 billion. Alvotech recently reported positive top-line results from a confirmatory clinical study comparing AVT06 with Eylea in patients with neovascular (wet) AMD, demonstrating therapeutic equivalence and comparable safety.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has closed a senior secured first lien term loan facility. This refinancing move has allowed Alvotech to reduce its cost of capital and improve its debt maturity profile. The company now has total gross borrowings of $1,035 million and a cash balance of $185 million. The new facility includes a $900 million term loan at SOFR plus 6.5% and a $65 million term loan at SOFR plus 10.5%, both maturing in June 2029. Alvotech plans to use the available cash to advance its development pipeline and support working capital requirements for ongoing and upcoming biosimilar launches.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced its schedule for reporting financial results for the first half of 2024. The company will release its financial results on August 15, 2024, after U.S. markets close. Following this, Alvotech will host a conference call on August 16, 2024, at 8:00 am EDT (12 noon GMT) to present the financial results and recent business highlights to analysts.
The conference call will be accessible via webcast to news media, investors, and the general public. Details for accessing the webcast or participating in the conference call are available on Alvotech's investor website. A replay of the webcast will be archived and available for 90 days after the event.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has issued 22,073,578 new ordinary shares to holders of subordinated convertible bonds. The conversion occurred at a fixed price of US$10.00 per share. These bonds were originally issued on November 16, 2022, and December 20, 2022, with a maturity date of December 20, 2025. Most of the bondholders exercising their conversion rights are existing Alvotech shareholders. Following this conversion, Alvotech's total issued shares have increased to 324,801,040, with 301,944,470 outstanding shares. The newly issued shares will be delivered to their owners within seven business days.
Alvotech (NASDAQ: ALVO), a global biotech company specializing in biosimilar medicines, announced that the majority of holders of its subordinated convertible bonds will convert their holdings into ordinary shares. The conversion will occur on July 1, 2024, at a fixed price of $10.00 per share. Based on current exchange rates, Alvotech estimates issuing approximately 22.1 million new shares.
All holders of the ISK-denominated Convertible Bonds (Tranche A) have opted for conversion, with an aggregate value of about $183.1 million. For USD-denominated bonds, holders of approximately $38 million worth have chosen to convert, while holders of about $116.7 million have not exercised their conversion rights. The newly issued shares will be delivered within seven business days after the Conversion Date.
STADA and Alvotech have launched Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across major European markets. This launch comes immediately after the expiry of exclusivity rights for the reference molecule, creating competition and potentially broadening patient access in a market estimated at €2.4 billion. Uzpruvo is indicated for Crohn's disease, psoriatic arthritis, and plaque psoriasis in adults and children from 6 years old.
Uzpruvo offers a pre-filled syringe with a thinner needle and is latex-free. It's the second immunology biosimilar brought to market through the STADA-Alvotech partnership, following the 2022 launch of Hukyndra (adalimumab). The biosimilar is developed, manufactured, and packaged entirely within Europe, with a 36-month shelf life.
Alvotech and STADA are expanding their strategic alliance for biosimilars by extending their partnership to include AVT03, a biosimilar candidate for Prolia®/Xgeva® (denosumab). This medication targets osteoporosis and cancer-related bone loss. Under the agreement, Alvotech will handle development and manufacturing, while STADA will manage commercialization in Europe, including Switzerland and the UK, as well as selected countries in Central Asia and the Middle East.
The partnership also extends STADA's commercial rights for Humira® and Stelara® biosimilars to CIS countries in Central Asia. Alvotech regains commercial rights to AVT06, a proposed Eylea® biosimilar. This expansion builds on their successful collaboration, which has already launched Hukyndra®, a high-concentration Humira® biosimilar, in Europe.
Alvotech (NASDAQ: ALVO), a global biotech firm, has successfully secured a strategic refinancing deal led by GoldenTree Asset Management, involving multiple institutional investors. This transaction provides a senior secured first lien term loan of up to $965 million in two parts: a $900 million term loan at SOFR plus 6.5% interest, and a $65 million optional term loan at SOFR plus 10.5% interest. The funding is set to mature in June 2029, with disbursement expected in July 2024.
Alvotech aims to utilize these funds to refinance outstanding debts maturing in 2025 and bolster its working capital for upcoming product launches. Chief Finance Officer Joel Morales emphasized that the facility would enhance financial flexibility and support long-term growth, projecting significant revenue growth and market expansion for Alvotech's biosimilars.